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The M128L myxoma virus gene expresses a five-membrane spanning cell surface protein with significant amino acid homology to the
cellular CD47 proteins. CD47, also called integrin-associated protein (IAP), is associated with the modulation of leukocyte adhesion,
motility, activation, and phagocytosis. Creation of an M128L-deletion mutant myxoma virus strain and subsequent infection of the European
rabbit demonstrated that M128L is necessary for the production of a lethal infection in susceptible rabbits, while it is fully dispensable for
virus replication in vitro. Secondary sites of infection developed on the majority of rabbits infected with the M128L-deletion mutant
(vMyx128KO), demonstrating that the M128L protein is nonessential for the dissemination of virus within the host. Although the size and
severity of the primary lesions on vMyx128KO-infected rabbits were comparable to rabbits infected with the wild-type virus at the early
stages of disease progression, by day 7 the reduced virulence of the vMyx128KO virus was clearly evident and all of the animals recovered
from infection by the M128L-knockout virus. Histological analysis of the tissues of vMyx128KO-infected rabbits revealed greater activation
of monocyte/macrophage cells in infected and/or lymphoid tissues when compared to those of wild-type myxoma-infected rabbits. We
conclude that the M128L protein is a novel CD47-like immunomodulatory gene of myxoma virus required for full pathogenesis of the virus
in the European rabbit and that its loss from the virus results in increased activation of monocyte/macrophage cells during infection.
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Myxoma virus is a member of the poxvirus family and
the prototypic example of the Leporipoxvirus genus, and is
the causative agent of myxomatosis in European rabbits, a
severely debilitating disease characterized by profound
systemic cellular immunosuppression and virtually 100%
rate of mortality in this host (Fenner, 1983; Fenner and
Ratcliffe, 1965). The complete 161.8-kb dsDNA genome of0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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E-mail address: mcfadden@robarts.ca (G. McFadden).myxoma virus (strain Lausanne) was sequenced and
analyzed to reveal a spectrum of potentially novel immuno-
modulatory genes (Cameron et al., 1999). Bioinformatic
analyses of the predicted protein products of the 159 unique
identified open reading frames revealed several host-related
proteins, including a family of proteins with multiple
ankyrin-repeat domains, a CD200-like protein, three ser-
pins, a chemokine binding protein, several cytokine receptor
homologs, a growth factor, a complement inhibitor, and a
number of proteins with domains closely related to diverse
host immune regulatory proteins (Barrett et al., 2001;
Cameron et al., 1999). The M128L gene was one of the
newly identified myxoma genes with the potential for an
immune-related function based on its predicted immuno-005) 55 – 67
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CD47 molecule.
The predicted myxoma virus M128L gene product
shares approximately 23% identity with bovine CD47
under optimal pairwise alignment conditions and over the
entire length of the protein (Cameron et al., 1999). Other
CD47 homologues have been identified within the genomes
of many, but not all, of the chordopoxvirus subfamily
members sequenced to date; members of the orthopoxvirus,
capripoxvirus, leporipoxvirus, suipoxvirus, and yatapoxvi-
rus genera as well as deerpox, an unclassified chordopox-
virus (Afonso et al., 2005), possess CD47-like genes (Seet
et al., 2003). CD47-like genes have not been identified to
date in the sequenced members of the parapoxvirus,
avipoxvirus, or molluscipoxvirus genera. CD47 homologs
have not been described in the sequenced members of the
entomopoxvirus subfamily, nor have they been recognized
as occurring in other virus families, such as herpesviridae,
which are large dsDNA viruses known to encode multiple
immunomodulatory proteins.
The only viral CD47-like gene which has been previ-
ously characterized is vaccinia virus Western Reserve strain
A38L, which shares 28% amino acid (aa) identity in the N-
terminal immunoglobulin-variable (IgV)-like domain region
with that of mammalian CD47 (Parkinson et al., 1995), and
16% aa identity with M128L. The A38L gene was found to
encode a membrane-associated and glycosylated 33-kDa
protein that was expressed at low levels during late times of
virus infection, but not as a component of IMVor EEV. Loss
of the A38L gene from vaccinia virus resulted in a small
reduction in virus plaque size, but had no consequences
regarding the production of intracellular mature virus (IMV)
or extracellular enveloped virus (EEV) particles in tissue
culture cells. The A38L-deletion mutant virus did not
exhibit a loss of virulence in the murine intranasal model,
and therefore it was concluded that the virulence and virus
particle production of this strain of vaccinia were not
dependent upon A38L protein expression (Parkinson et al.,
1995). Further investigation of A38L function was carried
out using a recombinant vaccinia virus capable of inducibly
overexpressing the A38L protein, and demonstrated that
A38L overexpression results in profound observed differ-
ences in the characteristics of infected cells in terms of their
adhesion, permeability, and morphology (Sanderson et al.,
1996). Infected cells overexpressing the A38L protein
underwent cellular necrosis, increases in membrane perme-
ability, and finally Ca2+-dependent lysis. It was therefore
suggested that the A38L protein plays a role in plasma
membrane pore formation, enabling Ca2+ influx and
resulting in necrosis. In addition, it was noted that the
A38L overexpressing virus had a smaller plaque size, as did
the A38L-deletion mutant, and resulted in the creation of
fewer particles in vitro (Sanderson et al., 1996).
Mammalian CD47 is a unique member of the immuno-
globulin superfamily, possessing a single extracellular N-
terminal immunoglobulin domain, five transmembranedomains, and a relatively small cytoplasmic domain (Brown
and Frazier, 2001). Alternatively spliced isoforms of CD47
exist, with all splice variants mapping in the intracytoplas-
mic domain (Lindberg et al., 1993). CD47 is ubiquitously
expressed as a 50-kDa cell-surface protein, with one of its
four major isoforms found on most cell-types including
erythrocytes (Reinhold et al., 1995). CD47 was initially
discovered as a surface protein that copurifies with the
integrin avh3, but has subsequently been shown to
associate with other integrins as well, such as a2h1 and
aIIbh3 (Green et al., 1999; Wang and Frazier, 1998). This
physical association is biologically functional. Treatment of
cells with activating antibodies directed against CD47
results in the identical signaling cascade to that induced
by the activation of the coupled integrin, while treatment
with blocking antibodies to the CD47 molecule is able to
inhibit integrin signaling (Brown et al., 1990; Lindberg et
al., 1993). Importantly, CD47 has been shown to also act
independently of integrins and interact with a variety of
ligands which activate it directly (Barazi et al., 2002; Brown
and Frazier, 2001).
CD47 is a well-documented regulator of the vertebrate
immune response and exerts multiple functions on various
immune cell types (Brown, 2001; Brown and Frazier, 2001;
Pettersen, 2000). CD47 was shown to play a critical role in
host defense by Lindberg et al., who demonstrated that
CD47-deficient mice are more susceptible to bacterial
infection than heterozygous CD47(+/) littermates (Lindberg
et al., 1996). The polymorphonuclear cells of CD47-
deficient mice were found to have defects in migration
and activation during E. coli infection, both in vivo and in
vitro. In terms of the host response to an invading pathogen,
the ability of effector leukocytes to become activated is
ineffective if these same cells cannot reach the site of
infection. CD47 and its receptor, SIRPa (CD179a), appear
to regulate human polymorphonuclear cell chemotaxis (Liu
et al., 2002), and antibodies to CD47 augment the
proliferation of primary human T cells and increase their
expression of CD25 and IL-2 (Reinhold et al., 1997;
Ticchioni et al., 1997). In fact, CD47 ligation on a mixed
population of naive human mononuclear cells has been
shown to foster the development of anergic T cells, with
defects in IL-2 and cytokine production, proliferation, and
ability to respond to IL-2, IL-4, or IL-12 (Lindberg et al.,
1996).
It has also been shown that activation of CD47 on the
surface of monocytes inhibits proinflammatory cytokine
release, specifically that of TNF-a, IL-12, and IFN-g
(Armant et al., 1999; Hermann et al., 1999). Similarly,
mAb-induced activation of CD47 at the surface of immature
dendritic cells inhibits the production of TNF-a, IL-12, GM-
CSF, and IL-6 (Demeure et al., 2000). CD47 has also been
shown to play a role in determining the destiny of activated T
cells through a novel apoptotic pathway not dependent on
CD3, CD4, CD45, or p56lck (Avice et al., 2001; Mateo et al.,
1999; Pettersen et al., 1999). These findings make evident
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inflammatory response, not only by modulating the activity
of effector leukocytes, but also by regulating professional
antigen-presenting cells, limiting their expression of inflam-
matory cytokines and effective maturation.
The abundance and variety of roles played by CD47 in
the immune system led us to further investigate the
possibility that M128L, the myxoma CD47-like protein,Fig. 1. (A) Alignment of bovine CD47, myxoma M128L, and swinepox virus 125.
sequences denote the predicted membrane-spanning domains of the cellular protei
define the Ig domain boundary. Asterisks denote conserved predicted N-glycosyl
terminal signal sequence. The box at position 266–268 of M128L denotes a pred
Note that the molecules are strikingly similar in terms of location of their predicted
features of the M128L protein, including five transmembrane domains and 6 poten
SMART is labeled. (C) Neighbor-joining tree of myxoma M128L and selected m
Branch numbers refer to bootstrap analysis.might function as a virulence factor that targets reactive
leukocytes in the rabbit host. The well-characterized patho-
genesis of myxomatosis provides us with a useful model
with which to dissect the role of specific virulence factors
during poxvirus infection (Best and Kerr, 2000; Best et al.,
2000; Johnston and McFadden, 2004; Kerr and McFadden,
2002). This paper is an initial characterization of the role of
the M128L protein in providing myxoma virus with aAA identities are indicated by black boxes. Bold lines above and below the
n and its viral homologues. Arrows denote the two conserved cysteines that
ation sites. Jagged arrowheads depict the predicted cleavage site of the N-
icted Protein kinase C phosphorylation site within the cytoplasmic domain.
membrane-spanning domains. (B) Cartoon depicting the predicted structural
tial N-glycosylation sites (Y). An immunoglobulin (Ig) domain predicted by
embers of the cellular and viral members of the CD47-like gene family.
Fig. 2. (A) Location of peptide used for production of anti-M128L polyclonal antibody. M128L peptide was chosen based on antigenic index and location within
the predicted secondary structure of M128L protein (i.e., not within cleavable signal sequence or transmembrane domain, nor within proximity to predicted
disulfide bond). Peptide sequence is DTISNKTNGSSITFDC. (B) M128L was expressed by vMyxgfp, with an observed molecular mass of 31 kDa.
BGMK cells were infected (moi=3) and aliquots taken at 0 h (lane 1), 4 h (lane 2), 8 h (lane 3), 12 h (lane 4), 24 h (lane 5), and 48 h (lane 6). (C)M128L expression
requires synthesis of viral DNA. Lysates of vMyxgfp-infected BGMK cells (lanes 1 and 2) and RK13 cells (lanes 3 and 4) were collected 48 hpi. Lysates in lanes
2 and 4 were from cells treated with AraC (40 Ag/ml), an inhibitor of DNA synthesis, while lysates in lanes 1 and 3 are from untreated cells.
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persist and survive in the face of the host immune response.Results
Myxoma virus M128L resembles CD47
The M128L open reading frame was identified by the
sequencing of the myxoma virus genome and was predictedFig. 3. Confocal immunofluorescence analysis demonstrating the cell-surface ex
vMyxgfp-infected cells stained with anti-M128L antibody, (B) Lausanne (wi
vMyx128KO-infected cells stained with anti-M128L antibody, (D) mock-infected
Fig. 4. (A) Construction strategy of the myxoma virus M128L-deletion mutant L
flanking regions (M128LFL/M128LFR) of the M128L gene. (B) After several ro
and the viral genomic DNAwas used as a template to determine the purity of the re
between M128LFL and M128LFR, resulting in a product of approximately 2 kb w
the larger molecular weight EGFP/gpt cassette has replaced all but the flanking reg
1 and 2 are the products of PCR reactions carried out using wild-type myxoma
reactions carried out using purified vMyx128KO isolate genomic DNA as templa
primer pair M127L+M128L, designed to amplify the undisturbed region between
2 and 4 used the primer pair M127L+M129R, designed to amplify the region ofto encode a protein of 281 aa and 32.1 kDa (Cameron et al.,
1999). Initial blast search analysis suggested that M128L
shared sequence homology with the family of CD47 proteins
(Fig. 1A). Subsequent SMART analysis revealed that
M128L’s predicted domain architecture (Fig. 1B) followed
expectations based on CD47-like family of proteins (Alt-
schul et al., 1990; Letunic et al., 2004). Structural analysis of
the amino acid sequence predicted that M128L encodes an
N-terminal cleavable signal sequence, a single variable (V)-
like immunoglobulin (Ig) domain, 6 potential N-glycosyla-pression of M128L during myxoma virus infection of BGMK cells. (A)
ld-type myxoma)-infected cells stained with anti-M128L antibody, (C)
cells stained with anti-M128L antibody (all at 1/500 dilution).
ausanne (wt) myxoma genomic DNA was used as template to amplify the
unds of drug selection and focus purification, foci were isolated, amplified,
combinant. Primers M127L and M129R were designed to amplify the region
hen the M128L gene is intact and a product of approximately 2.9 kb when
ions of the M128L orf. Genomic DNA templates used were as follows: lanes
genomic DNA as template, while lanes 3 and 4 are the products of PCR
te. The PCR reactions run in lanes 1 and 3 were amplified from the control
M128L’s flanking left sequence and M127L. The PCR reactions run in lanes
recombination between M128L’s flanking left and right sequences.
Fig. 3.
Fig. 4.
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primary sequence also contains an immunoglobulin (Ig)
domain, and there is significant conservation of cysteine
residues and flanking amino acids that map to the cellular
CD47 Ig domain. There is an estimated 23% sequence
identity shared between M128L and its closest cellular
counterpart, bovine CD47. Neighbor-joining tree analysis of
M128L and selected members of the cellular and viral
members of the CD47-like gene family shows that its
closest viral counterpart is the Shope fibroma virus S128L
(Willer et al., 1999), followed by the swinepox virus
SPV125 (Fig. 1C). The vaccinia A38L protein is the only
family member characterized to date in the poxvirus family
(Parkinson et al., 1995; Sanderson et al., 1996).
M128L is expressed as a 25- to 32-kDa cell surface protein
To aid in the characterization of M128L function, we
designed a peptide from predicted antigenic regions within
M128L and immunized a naive rabbit in order to raise
polyclonal antibodies to the viral protein (Fig. 2A). Screen-
ing of the rabbit serum indicated that reactive antibodies
against the M128L peptide were generated (not shown). To
study the expression of M128L during infection, BGMK or
RK13 cells were infected with vMyxgfp, and at various
times post infection, whole cell lysates were prepared and
separated on SDS–PAGE. M128L protein expression was
detectable by 24 h postinfection in vMyxgfp-infected
BGMK cells (Fig. 2B). This is later than expected based
on our tentative prediction of an early promoter for M128L
(Cameron et al., 1999), but may be the result of a low level
of gene expression or the limits of detection of the M128L-
peptide antibody, or a combination of both factors. To
confirm the apparent expression of M128L at late times,
infections carried out in the presence of AraC abolished
expression of M128L (Fig. 2C). Thus, M128L is apparently
expressed from a late promoter, but the precise mapping of
this promoter that drives the expression of M128L remains
to be deduced and is likely different from the presumptive
early promoter assigned in the original sequencing annota-
tion (Cameron et al., 1999).
The predicted signal sequence and multiple membrane-
spanning domains strongly suggested that M128L protein
would be localized at the cell surface. To test whether we
could detect M128L at the surface of infected cells, we
infected BGMK cells with wild-type myxoma virus (no
gfp), vMyxgfp, or vMyx128KO (expresses gfp: described
next section), and stained with anti-M128L antibody. Using
confocal immunofluorescence microscopy, we were able to
visualize M128L protein with anti-M128L antibody and
secondary antibody tagged with red fluorescent Cy5 stain.
The M128L protein was clearly detected at the surface of
non-permeabilized vMyxgfp- and wild-type-infected
BGMK cells (Figs. 3A and B). However, no M128L
expression was detectable at the surface of cells infected
with vMyx128KO (Fig. 3C). Nonspecific staining wasminimal in uninfected cells (Fig. 3D) or with secondary
antibody staining alone (not shown).
M128L is not required for in vitro myxoma virus replication
Targeted disruption of a specific viral gene represents a
fundamental tool for assessing the role of that given gene
during virus infection (Johnston and McFadden, 2004).
Therefore, we generated a recombinant myxoma virus in
which 720 of the 846 total nucleotides of the M128L open
reading frame were deleted and replaced with an EGFP/gpt
cassette (Fig. 4A). The knockout virus was prepared and
construct purity was confirmed by PCR amplification of the
M128L locus (Fig. 4B).
We hypothesized that M128L has an immunomodulatory
function during myxoma virus infection of rabbits and thus
could be non-essential for viral replication in cell culture. In
order to determine whether M128L plays a role in the in vitro
replication of myxoma virus, the growth kinetics of
vMyx128KO and wild-type virus strains were evaluated
and compared using conventional single step growth analyses
in cultured rabbit RK-13 fibroblasts, primate BGMK cells,
and the rabbit CD4+ T-lymphocyte cell line RL-5 (Fig. 5). No
obvious differences in growth or replication kinetics were
observed for vMyx128KO compared to wild-type control
viruses in the cell lines tested. Furthermore, we did not
observe any decrease in focus size with vMyx128KO when
grown onBGMK cell monolayers, unlike what was described
for the vaccinia A38L-deletion mutant’s decrease in plaque
size (Parkinson et al., 1995). Our growth kinetic analysis
confirmed that M128L was dispensible for virus infection
and replication in vitro.
M128L is a virulence factor in myxoma-infected rabbits
To examine the pathogenesis-enhancing capacity of
M128L, we infected NZW rabbits with control myxoma
virus (vMyxgfp), or vMyx128KO, and monitored the daily
progression of myxomatosis. Table 1 outlines the gross
pathological observations made at days 0, 4, 7, and 9
postinfection. Each of the vMyx128KO-infected animals
made a complete recovery following a delayed course of
myxomatosis, in which the rabbits suffered relatively mild
symptoms with reduced size and severity of primary lesions,
restricted spread and establishment of secondary lesions, and
a generally healthier attitude (Table 1). To confirm that the
attenuated virulence of our vMyx128KO strain was due
solely to interruption of theM128L gene, and not the result of
inadvertent mutations introduced elsewhere in the genome, a
revertant virus termed vMyx128rev was generated by
infection of BGMK cells with vMyx128KO followed by
transfection with a plasmid containing the intact M128L
gene. This resulted in the restoration of the M128L open
reading frame via homologous recombination, and coincident
removal of the EGFP/gpt cassette. Revertant virus was
generated by multiple rounds of selection for single foci
Fig. 5. Single step growth analysis of vMyx128KO, vMyxgfp, and vMyx
wild-type control Lausanne (vMyx) viruses on BGMK, RK13, and RL-5
cell lines. Cell lines were infected with virus at a multiplicity of infection of
5. Cells were harvested at the time points postinfection indicated on the x-
axis, and the titers of infectious virus present at each time point were
determined by subsequent infection on BGMK cells. All growth analyses
were performed in triplicate.
Table 1
Pathogenicity of vMyx128KO mutant myxoma virus in European rabbits
D.P.I. Wild-type control virus
(vMyxgfp)a
M128-deletion mutant
virus (vMyx128KO)
0 Inoculation of four rabbits
with 1000 pfu vMyxgfp
per site on each hindlimb
Inoculation of three rabbits with
1000 pfu vMyx128KO virus
per site on each hindlimb
3 Primary lesions appear:
pink, raised (<1 cm),
conjunctivitis 1 rabbit
Primary lesions appear:
pink/red, slightly raised
7 Primary lesions protuberant,
raised approximately
1–2 cm, necrotic, 6–14 +
satellites (0.7–2.5 cm),
ears thick with 2–15 +
coalescing lesions at base
(0.5–4.0 cm), multiple
lesions nose (2.2 cm),
1–6 eye lesions
(0.5–1.0 cm), copious
exudate from eyes,
1–2 genital lesions,
anxious behavior
Primary lesions begin to cavitate,
become less protuberant,
3–5 satellites (0.5–1.6 cm),
3–6 ear lesions (0.7–2.7 cm),
0–3 eye lesions (0.9–1.0 cm),
conjunctivitis, tiny nose lesion
1 rabbit, 2 tiny genital lesions
1 rabbit
9 Primary lesions extremely
protuberant and severely
necrotic (open wound),
copious exudate from
primary, 8 or completely
coalescing thick purple ear
lesions, multiple lesions
nose/lips, eyes swollen shut,
multiple genital lesions
(2.1 cm), very edematous
head, rough fur, abnormal
posture/activity, decreased
food and water intake,
decreased fecal output,
dehydration, abnormal
respiration, all rabbits score
as moribund and euthanized
Primary lesions healing,
3–4 satellites (1.0–1.3 cm),
2–5 ear lesions (0.5–1.0 cm),
1–2 eye lesions (0.4–1.0 cm)
21 n/a Primary lesions consist of
small, dry scabs, few scars
remain from secondary lesions,
all rabbits immune to challenge
with 2000 pfu vMyx
(Lausanne) per rabbit
a Symptoms listed are indistinguishable from those observed with
vMyx128rev-infected rabbits.
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in the revertant strain vMyx128rev, confirming thatM128L is
a critical virulence factor for myxoma virus in the infection of
the European rabbit.
In combination with the detailed observation of the
clinical symptoms associated with myxomatosis, rabbits
were evaluated daily for a defined list of diagnostic features
including quality of primary lesions, food and water intake,
fecal output, hydration level, respiration stress, quality and
quantity of satellite and secondary lesions on nose, eyes, ears,
and genitals, posture, activity, and attitude. Each diagnostic
feature was numerically evaluated according to well-defined
parameters set forth by the veterinarian, and clinical scores
were used to assist the animal care staff in monitoring
progression of myxomatosis. Certain symptoms such as
severe orthopnea, mouth breathing, cyanosis, and lack of
food and/or water intake for > 24 h required that the rabbitsbe euthanized for ethical reasons. The clinical scores for
both vMyx128KO- and vMyxgfp-infected rabbits suggested
that it is not easy to differentiate between animals infected
with either virus before day 7 postinfection. After 7 days
postinfection, however, the diagnostic scores diverged, with
the scores for the rabbits infected with vMyxgfp or
vMyx128rev increasing markedly versus a decrease in
scores for the vMyx128KO-infected (Fig. 6). The vMyxgfp-
infected group exhibited a rapid and continuous increase in
clinical scores to the point at day 9 postinfection where
euthanasia was required. On the other hand, the peak of
clinical scores for the vMyx128KO-infected animals
occurred at day 7 postinfection. Once the vMyx128KO
rabbits had recovered fully, they were re-challenged by
Fig. 6. vMyx128KO pathogenesis study. Three rabbits were infected with
the vMyx128KO virus, 3 rabbits with the vMyx128rev virus, and 4 rabbits
with the vMyxgfp control virus. The rabbits were each infected with 2000
pfu intradermally, 1000 pfu injected into each hindleg. Rabbits were
monitored daily for the clinical symptoms associated with myxomatosis.
Scores increase as disease progresses. Animals are normally sacrificed
within 24–48 h once a score of 15 is reached.
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completely protected from myxomatosis. Based on the
results of this study, we conclude that the M128L protein
plays a crucial role in the pathogenesis of myxoma virus and
can therefore be classified as a bona fide virulence factor.
M128L contributes to downregulation of macrophage
activation
The effects of cellular CD47 on the activation and
function of myeloid lineage cells led us to investigate
whether or not we could detect changes in the levels of
macrophage activation in vivo following vMyx128KO and
vMyxgfp infection of rabbits. Primary lesions and popliteal
and inguinal lymph nodes from rabbits infected with
vMyx128KO or vMyxgfp were harvested at 3 and 7 days
postinfection. Tissues were then probed with anti-iNOS
monoclonal antibody, and positively staining iNOS-express-
ing cells were quantified in the tissues of vMyx128KO- and
vMyxgfp-infected rabbits.
Although at day 3 postinfection significant increases in
numbers of iNOS+ cells were seen in the tissues of
vMyx128KO-infected rabbits, a more profound discrepancy
in levels of macrophage activation was evident at day 7
postinfection. Significantly more iNOS+ cells were detected
in the primary lesion, inguinal, and popliteal lymph nodes by
day 7 in vMyx128KO-infected rabbits as compared to the
vMyxgfp-infected rabbits (Fig. 7A). At this time point, the
inguinal lymph nodes showed an average 5 iNOS+ cells/FOV
in vMyx128KO-infected rabbits versus <1 iNOS+ cells/
FOV from vMyxgfp-infected rabbits (Fig. 7B). The
popliteal lymph nodes showed an average 18 iNOS+
cells/FOV in vMyx128KO-infected rabbits versus <1
iNOS+ cells/FOV from vMyxgfp-infected rabbits. The
primary sites of infection showed an average 20 iNOS+cells/FOV in vMyx128KO-infected rabbits versus 4 iNOS+
cells/FOV from vMyxgfp-infected rabbits. Differences seen
in the lymph nodes were more extensive than those seen at
the primary site of infection (Fig. 7A). We conclude that
M128L plays a role during myxoma virus infection in
controlling macrophage activation and that deletion of
M128L from the myxoma virus genome allows the
activation and/or recruitment of iNOS+ cells to critical sites
of infection and immune organs during infection.Discussion
When compared to the cellular CD47 amino acid (aa)
sequence, M128L exhibits the highest conservation of aa
identity and similarity in the V-like Ig domain and a high
degree of overlap in the 5 predicted transmembrane domains
(Fig. 1A). This is critical in that it is through the N-terminal
immunoglobulin domain that CD47 interacts with the
inhibitory SIRPa family members (Brooke et al., 2004;
Han et al., 2000; Liu et al., 2004). Based on the known
immune regulatory function of cellular CD47, the genomic
location of M128L, and its absence from certain poxvirus
genomes, one would not predict that M128L would be
required for virus replication in vitro. Indeed, the deletion of
the M128L gene had no effect on the ability of the
vMyx128KO virus to replicate in any of the cultured cell
lines tested. M128L was predicted to possess a signal
sequence and five transmembrane domains, and we observed
that it localized to the cell membrane in cells infected with the
wild-type myxoma virus. This finding is consistent with a
putative CD47-like function for M128L, as it would require
exposure of the V-like Ig domain to the extracellular milieu
for the localized delivery of restrictive signals to local
myeloid-lineage cells. The attenuated pathogenesis of the
vMyx128KO is also consistent with the prediction that loss of
M128L should result in decreased ability to inhibit the
activation of immune effector cells.
This paper constitutes the first characterization of a viral
CD47 homolog as a virulence factor. Vaccinia A38L, the only
previously characterized CD47-like virus protein, was shown
not to play a role in the virulence of vaccinia virus during
infection of the mouse (Parkinson et al., 1995). M128L
appears to share many characteristics with the A38L protein.
We have established thatM128L encodes a 25- to 32-kDa cell
surface protein, which is not dissimilar to the 33-kDa
observed molecular weight of the membrane-associated
A38L gene product. Both M128L and A38L proteins were
expressed at low levels during late times of virus infection.
Finally, M128L and A38L were both shown to be dispensible
for virus replication in vitro.
Although loss of the A38L gene from the vaccinia strain
WR resulted in a small reduction in plaque size in tissue
culture cells, we did not note any changes in the size of
vMyx128KO foci. This seeming discongruity could be
explained by differences in the manifestation of infection in
Fig. 7. Activated macrophage levels in myxoma-infected rabbits are modulated by M128L. (A) Numbers of iNOS-expressing cells present in inguinal and
popliteal lymph nodes, and primary lesions of vMyx128KO- and vMyxgfp-infected rabbits at 7 days postinfection. Tissues were harvested and snap frozen in
OCT media at day 7 postinfection and stained with anti-iNOS monoclonal antibody as outlined in Materials and methods. Data shown are average numbers of
positively-staining cells for five randomly selected 20 fields of view (FOV) per tissue per rabbit, with 2 rabbits per group (virus and day postinfection). (B)
Primary lesion, popliteal, and inguinal lymph node tissue sections from vMyx128KO- and vMyxgfp-infected rabbits. Tissues were harvested and snap frozen in
OCT media at day 7 postinfection and stained with anti-iNOS monoclonal antibody as outlined in Materials and methods. 20magnification, scale bar = 10 Am.
C.M. Cameron et al. / Virology 337 (2005) 55–67 63tissue culture, since vaccinia infection eventually results in
the lysis of infected cells and forms plaques on a confluent
monolayer, while myxoma virus is non-lytic and simply
forms foci on cell monolayers. Small alterations in focus size
may be less obvious than changes in plaque size due to
dimensional inequality of the focus and the plaque.
While the M128L-deletion mutant exhibited a profound
loss of virulence in the host rabbit, such a defect was not
observed with the A38L-deletion mutant virus using the
murine intranasal model (Parkinson et al., 1995). Again, there
are a number of possible explanations for this seeming
inconsistency. For instance, while the virulence of this
particular strain (WR) of vaccinia virus does not depend
upon A38L protein expression in this particular strain of mice
(female BALB/c), deletion of the A38L protein may
demonstrate a reduction in virulence using a different strain
of vaccinia virus and/or mouse, or during the infection of an
entirely different species of host. The mouse is not the naturalhost of vaccinia, and intranasal inoculation may bypass the
requirement for A38L function for productive infection.
Perhaps another route of infection would reveal that the loss
of A38L expression has an impact on virulence in the mouse.
The symptoms used to evaluate the virulence of the A38L-
deletion mutant may not be sufficiently sensitive to detect
statistically significant variation. Alternatively, it may be that
our control myxoma virus strain is much more virulent and
allows a greater window of sensitivity for ascertaining
changes in virulence. The evolution of myxoma virus within
lagomorph hosts is well established, which facilitates and
validates the assessment of virulence, while the natural host
of vaccinia is as yet undetermined. Moreover, myxoma virus
is much more consistently lethal and severely pathogenic in
the rabbit (Oryctolagus cuniculus) host, and therefore the in
vivo model of myxomatosis has the potential to offer a more
sensitive measure of changes in virulence (Kerr and
McFadden, 2002). Although it is highly unlikely, it cannot
C.M. Cameron et al. / Virology 337 (2005) 55–6764be ruled out at this point that the diverse replication cycles of
the two viruses may have resulted in selection for disparate
functions for A38L and M128L within the host.
Although the evidence provided for the function of the
vaccinia CD47-like protein was not indicative of an
immunomodulatory role for vaccinia pathogenesis in the
mouse, the wide-ranging immunoregulatory functions of the
cellular CD47 protein prompted us to examine the function of
the myxoma CD47 homolog in infected rabbits. Based on the
functional characterization of the cellular CD47 proteins, we
reasoned that a defect in subsequent activation of myeloid-
lineage cells could result from contact with M128L protein.
We assessed macrophage activation by staining for the
expression of the inducible form of nitric oxide synthase
(iNOS). Using iNOS induction, we observed significant
differences in the numbers of activated macrophage with the
capacity to generate high levels of the viro-toxic compound
NO when comparing wild-type and vMyx128KO-infected
rabbits. Thus, a robust upregulation of iNOS expression
occurred specifically in tissues of rabbits infected with the
myxoma virus lacking M128L as compared to the M128L-
expressing parental virus. This is consistent with the model
that M128L induces CD47-like inhibitory signals to macro-
phages, and potentially resident dendritic cells as well,
possibly by activation of the CD47 receptor SIRPa.
The antiviral activity of NO has previously been
demonstrated in poxvirus infections (Karupiah et al.,
1993). The ability of IFN-g to limit both ectromelia and
vaccinia virus replication corresponds to the production of
NO, since macrophages treated with NOS inhibitors allow
complete recovery of virus replication. In vivo experiments
involving the treatment of mice with an NOS inhibitor,
followed by ectromelia infection, resulted in the develop-
ment of fulminant mousepox instead of the normal course of
ectromelia infection (Karupiah et al., 1993). NO itself can
be used therapeutically to improve the course of poxvirus
infection in humans. A clinical trial of acidified nitrite (an
NO donor) was carried out to evaluate its efficacy in
treating molluscum contagiosum (a skin disease cause by
infection by the poxvirus molluscum contagiosum)
(Ormerod et al., 1999). Compelling evidence for the
inhibition of poxvirus virulence by NO was provided by
experiments in which mice were infected with a vaccinia
virus expressing iNOS, and inhibition of virus replication
was evident at 24 h postinfection (Rolph et al., 1996). We
postulate that M128L expression results in a decreased
ability of myeloid-lineage cells to locally express the
inducible form of NOS, thereby strictly limiting the
localization generation of viro-toxic free radicals, as well
as likely dampening other related anti-viral activities such
as phagocytosis and antigen presentation. The dramatically
increased numbers of activated macrophages within the
tissues of rabbits infected with the vMyx128KO virus as
compared to those infected with vMyxgfp suggest that the
M128L protein plays a direct role in undermining the
activation of these cells during myxoma virus infection.Recently, another myxoma protein (M141R) has also been
shown to contribute to the downregulation of macrophage
activation (Cameron et al., 2005), thus emphasizing the
critical role that macrophages play in the anti-viral response.
The mechanism of M128L’s ability to inhibit the
activation of macrophages within the host is not obvious;
however, we would like to suggest a potential explanation
for the observed consequences of lack of M128L expression
at the surface of vMyx128KO-infected cells. Myxoma virus
infection downregulates the expression of many host cell
proteins and could possibly result in decreased levels of
CD47. Reduced levels of CD47 protein paired with the
absence of CD47-like protein (M128L) at the surface of an
infected cell could diminish its capacity to inhibit macro-
phage inflammatory signaling pathways via SIRPa, and the
negative signal is minimized. The pathways leading to
upregulation of inflammatory functions, such as generation
of iNOS and its product, NO, might be favored, and thus
macrophages become more capable of mounting an
effective anti-viral immune attack.
In conclusion, we have characterized the M128L protein
as a potent immunomodulatory virulence factor expressed
by myxoma virus, and propose that it functions as a bona
fide mimic of host CD47. M128L expression provides a
selective in vivo advantage to myxoma virus, and this likely
relates to the ability of M128L to inhibit the activation of
myeloid-lineage cells. Further experiments to determine if
the M128L protein is able to bind and signal via SIRPa or
any of the other known cellular CD47 interacting proteins
would allow testing of the model that M128L is an agonistic
ligand of the CD47 family that downregulates the activation
of myeloid cells in the infected host.Materials and methods
Cells and virus strains
Three strains of myxoma virus were used in these
experiments: (1) wild-type myxoma virus (vMyx), which
refers to strain Lausanne unless otherwise stated, (2)
vMyxgfp, which contains an enhanced green fluorescent
protein (EGFP) open reading frame inserted between ORF
135 and 136 and under the control of a vaccinia virus
synthetic early/late promoter (Johnston et al., 2003), and (3)
vMyx128KO, the M128L-deletion recombinant myxoma
virus. All virus strains were routinely passaged and titrated
by focus formation on BGMK cells as described previously
(Opgenorth et al., 1992). For single-step growth analyses,
virus strains were passaged on baby green monkey kidney
(BGMK) cells (obtained from Dr. S. Dales, University of
Western Ontario) and rabbit kidney (RK13) cells (ATCC
CCL-37) both maintained in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal bovine
serum (FBS, Gibco BRL), 100 U of penicillin/ml, and
100 Ag of streptomycin/ml. As well, we used rabbit
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Health AIDS Reagent Program) maintained in RPMI
1640 (Gibco BRL) supplemented with 10% FBS, 100 U
of penicillin/ml, and 100 Ag of streptomycin/ml.
Construction of recombinant myxoma virus strains
In order to generate a myxoma virus strain lacking the
M128L open reading frame, vMyx genomic DNAwas used
as a template to amplify the left and right flanking regions
(M128LFL and M128LFR), respectively, of the M128L
gene with BamH1 (M128LFL) or SpeI (M128LFR) sites at
both ends. M128LFL was ligated into pT7 E/L EGFP/gpt
plasmid following digestion with BamH1. The recombinant
plasmid was amplified and digested with SpeI, and
M128LFR was then ligated to form a plasmid consisting
of the flanking regions of M128L on either side of the
EGFP/gpt cassette already inserted into a pT7Blue (Pro-
mega) backbone. Sequencing reactions in both directions
confirmed that no sequence errors had been introduced and
that the orientation of each of the inserts was correct. This
plasmid was subsequently transfected into vMyx-infected
BGMK cells to create, via homologous recombination, the
M128L-deletion mutant virus expressing EGFP and gpt
(vMyx128KO). After several rounds of gpt drug selection
and focus purification, viral genomic DNA was used as a
template to determine the purity of the recombinant. Primers
were designed to amplify the region between M128LFL and
M128LFR, resulting in a product of approximately 2 kb
representing the wild-type genotype and a product of
approximately 2.9 kb representing the insertion of the
EGFP/gpt cassette into the interrupted M128L locus. These
primers were used to confirm the replacement of an intact
M128L open reading frame (ORF) with the EGFP/gpt
cassette (vMyx128KO). In order to restore the complete
M128L ORF, a plasmid containing the intact M128L gene
was transfected into BGMK cells infected with vMyx128KO
to generate the vMyx128 revertant (vMyx128rev). Homo-
logous recombination between the M128L flanking regions
of the virus and the full-length M128L gene carried on the
plasmid resulted in the excision of the EGFP/gpt cassette
from the virus and replacement with the intact full M128L
gene, creating a colorless focus of infection. Multiple
rounds of single focus purification were carried out and
PCR analysis of the M128L gene from the revertant virus
genomic DNA was used to verify purity of the revertant
virus strain.
Single-step growth analysis in tissue culture
BGMK, RK13, and RL5 cells (1  105) were infected
with wild-type myxoma virus, vMyxgfp, or vMyx128KO at
a moi of 5 for 1 h. The inoculum was removed and the cells
were washed three times with serum-free medium and then
fed with medium supplemented with 10% FBS. Virus was
harvested at 0, 4, 8, 12, 24, and 48 h postinfection (hpi).Virus titers were determined by serial dilution and infection
of BGMK cells, followed by crystal violet staining of fixed
monolayers in order to visualize foci. All growth analyses
were performed in triplicate.
Generation of polyclonal anti-M128L antiserum
Peptide designed (DTISNKTNGSSITFDC) for produc-
tion of anti-M128L polyclonal antibody was based on
appropriate antigenic index, location within predicted
secondary structure of M128L protein (i.e., not within
cleavable signal sequence or transmembrane domain, nor
within proximity to predicted disulfide bond), as well as
ease of synthesis. Peptide was synthesized by Sigma
Genosys. Rabbit polyclonal M128L antiserum was gen-
erated using keyhole limpet hemocyanin (KLH)-conjugated
peptide as immunogen. Peptide was conjugated to KLH
using the Imject Immunogen EDC conjugation kit (Pierce)
according to the manufacturer’s instructions, and sus-
pended in Freund’s complete adjuvant (Sigma) for the
first injection into New Zealand White rabbits. Four to five
subsequent injections for boosting antibody production
were carried out in Freund’s incomplete adjuvant (Sigma).
Antibody titer was assessed using Western blot analysis of
vMyxgfp-infected BGMK cell lysates. Positive anti-
M128L serum was obtained, and antiserum was subse-
quently purified using a column for affinity purification
prepared with the M128L peptide conjugated to BSA using
the Aminolink Plus Immobilization Kit (Pierce) following
the manufacturer’s protocol.
M128L expression in infected cells
To examine the expression of M128L, BGMK or RK13
cells (5105) were infected with vMyxgfp at an moi of 3
for 1 h at 37 -C. At various times postinfection, infected
cells were collected and lysed with 50 Al RIPA buffer for 20
min on ice. Nuclei were removed by centrifugation.
Samples were analyzed by 12% SDS–PAGE and trans-
ferred to Hybond C+ (Amersham). The filters were blocked
at room temperature for 1 h in 5% skim milk/TBS/Tween
followed by overnight incubation at 4 -C with a 1:500
dilution of the affinity purified anti-M128L polyclonal
antibody in 5% skim milk/TBS/Tween. The blot was
washed once with TBS/Tween, then incubated for 60 min
with a 1:5000 dilution of goat anti-rabbit HRP (Jackson
Immunoresearch) secondary antibody in 5% skim milk/
TBS/Tween. The filter was then washed three times and
bands were detected using ECL Plus (Amersham). For the
experiments carried out to determine whether M128L was
an early or late gene, BGMK and RK13 were infected with
vMyxgfp at a moi of 3. Following 1-h adsorption of the
virus, the inoculum virus was removed, the cells were
washed, and the fresh medium, with or without AraC (40 Al/
ml), was applied. Cell lysates were collected 48 hpi and
treated as described above.
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viruses
Specific pathogen-free female New ZealandWhite rabbits
(O. cuniculus) were housed in Level II biocontainment
facilities designation as per Health Canada’s ‘‘Laboratory
Safety Guidelines’’, 2nd edition, and Canadian Food Inspec-
tion Agency (CFIA) guidelines for ‘‘Containment Standards
for Veterinary Facilities’’. All protocols and procedures were
in accord with the regulations of the Animals for Research
Act (Ontario) and the guidelines and policy statements of the
Canadian Council on Animal Care (CCAC). Each rabbit was
inoculated intradermally with 1000 PFU of virus per site, and
injections were performed in both hindlegs. The rabbits were
monitored twice daily by research and veterinary staff for
symptoms of myxomatosis, including but not limited to size,
number, and quality of primary and secondary lesions,
orthopnea, mouth breathing, cyanosis, decreased or absent
food/water intake, fecal output, and dehydration (Fenner and
Ratcliffe, 1965; McFadden, 1994). Moribund animals were
immediately sacrificed by i.v. injection with euthanyl
administered intravenously following anesthesia. For the
comparative pathogenesis study, three rabbits were inocu-
lated with vMyx128KO virus, three with vMyx (strain
Lausanne), and four with vMyxgfp. Disease progression
was followed for 28 days or until euthanasia was required.
For the histological study, six rabbits each were inoculated
with vMyx128KO or vMyxgfp. Two animals per group were
sacrificed at days 3, 7, and 10 postinfection. Primary and
secondary lesions, spleen, inguinal, and popliteal lymph
nodes were harvested, and paired samples of each were either
snap frozen in OCT media to cryopreserve them for later
sectioning or placed in neutral-buffered formalin.
Histology and immunohistochemistry
Immunohistochemistry was performed on both frozen
and formalin-fixed tissue sections. Rabbits were sacrificed
and selected tissues were fixed in 10% formalin, while a
paired sample for each tissue was snap-frozen in OCT
compound (Tissue Tek; Miles Diagnostics). Formalin-fixed
tissues were embedded in paraffin, cut into 5-Am-thick
sections, and stained with hematoxylin and eosin. Frozen
sections were incubated with anti-murine iNOS (BD Trans-
duction Laboratories). Slides were then processed using a
Vectastain ABC kit according to the manufacturer’s
instructions (Vector Laboratories). The reaction was then
developed using 3,3V-diaminobenzidine tetrahydrochloride
and analyzed by light microscopy. Non-fluorescent immu-
nohistochemistry (anti-iNOS staining) images were taken
using a Nikon OPTIPHOT microscope.
Immunofluorescence staining and fluorescence microscopy
1105 BGMK cells were seeded to near confluency
on 1-mm glass coverslips and allowed to adhere for 4 h at37 -C. Each of the virus strains (vMyx, vMyxgfp, or
vMyx128KO) was then used to infect cells at a moi of 1
focus forming unit (ffu) per cell for 1 h at 37 -C, followed
by the addition of fresh media. At 48 h postinfection (hpi),
the coverslips were washed three times in PBS and fixed
with 4% paraformaldehyde for 1 h at room temperature.
The fixed cells on coverslips were again washed three
times in PBS, and non-specific binding was blocked by
incubation in 4% FBS in PBS for 1 h at room
temperature. Coverslips were again washed three times
in PBS and incubated overnight at 4 -C with a 1:500
dilution of anti-M128L antiserum or pre-immune serum
in 4%FBS in PBS. Coverslips were washed three times
in PBS and then incubated in a 1:500 dilution of Cy5-
conjugated mouse anti-rabbit IgG H+L secondary anti-
body (Jackson Immunoresearch) in 4%FBS in PBS for 1
h at room temperature. Finally, coverslips were washed
three times with PBS and mounted onto slides for
examination by confocal microscopic analysis using a
Zeiss LSM 510 META NLO microscope with C-Apo
40/1.2 NA and C-Apo 63/1.2 NA (water immersion)
lenses.
Statistical and sequence analysis
All experiments were performed at least in triplicate.
Values are expressed as the meanT standard deviation of
individual samples. The myxoma virus M128L sequence
was previously submitted to GenBank and assigned
accession number NC_001132 (Cameron et al., 1999).
M128L sequence was analyzed using MacVector and
DSgene (Accelrys) and NCBI Blast.Acknowledgments
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